Olanzapine Pamoate is an atypical antipsychotic medication primarily used in the treatment of schizophrenia and bipolar disorder. It is a long-acting injectable formulation of olanzapine, which allows for extended therapeutic effects with less frequent dosing compared to oral forms. The substance is characterized by its ability to antagonize various neurotransmitter receptors, including dopamine D2 and serotonin 5-HT2A receptors, which contributes to its efficacy in managing psychotic symptoms. Olanzapine Pamoate is typically administered via intramuscular injection, providing a depot effect that maintains stable drug levels in the body over time. Its pharmacokinetics are influenced by factors such as patient metabolism and the specific formulation used. Common side effects may include sedation, weight gain, and metabolic changes, necessitating careful monitoring during treatment. As with any antipsychotic, the risk of extrapyramidal symptoms and other adverse effects should be considered. Overall, Olanzapine Pamoate represents a significant advancement in the management of severe psychiatric conditions, offering patients a more convenient and effective treatment option.

Olanzapine Pamoate

221373-18-8: Olanzapine pamoate [USAN], 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, 4,4'-methlenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1), monohydrate, 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine pamoate monohydrate, Unii-X7S6Q4Mhcb, Zyprexa Relprevv,  Olanzapine pamoate

Olanzapine Embonate Monohydrate CRS

Olanzapine pamoate monohydrate is a prodrug of the antipsychotic drug Olanzapine. It is used for the treatment of schizophrenia and bipolar disorder. The prodrug is converted to Olanzapine in vivo, which binds to histamine H1 receptors and blocks dopamine D2 receptors. This results in an antipsychotic effect, as well as a reduction in manic episodes associated with bipolar disorder. Olanzapine pamoate has been shown to be effective in treating schizophrenia, bipolar disorder, and major depressive disorder with psychotic features. The prodrug has also been shown to have a high oral bioavailability, good tissue distribution, and low toxicity.

CAS 221373-18-8: Olanzapine Pamoate

Olanzapine Embonate Monohydrate CRS

Ref: 41-Y0002175

Olanzapine pamoate monohydrate

Ref: 3D-FO26540

Olanzapine Pamoate Hydrate

Ref: ST-EA-CP-O1006